Meditation Trips: A Thematic Analysis of the Combined Naturalistic Use of Psychedelics With Meditation Practices

Meditative and psychedelic states have long been noted to share phenomenological features such as loosening of self-boundaries, feelings of unity and transcendence, and reductions in attachment to a fixed self. Earlier research has documented overlaps in psychological mechanisms (for example, increased mindfulness, nonreactivity, and decentering) and a handful of experimental studies have begun to test combinations of psychedelics and contemplative practices in retreat or laboratory contexts. Nevertheless, empirical work investigating how people combine psychedelics and meditation in naturalistic settings remains sparse. Azmoodeh and colleagues set out to explore how people who use classic psychedelics also use meditation outside formal therapeutic or retreat settings, and what subjective effects they report when meditating in close temporal proximity to psychedelic consumption. Using free-text responses collected within a larger online survey of psychedelic users, the study aimed to generate themes describing users' attitudes, behaviours, perceived benefits, harms, and practical considerations around what the authors term "psychedelic-meditation." This exploratory, hypothesis-generating approach was chosen because of the limited prior work on naturalistic combined use.

This qualitative study analysed free-text comments provided within a larger cross-sectional online survey of people with lifetime use of classic psychedelics. The research received University College London ethics approval and was not preregistered. Recruitment used convenience sampling via social media and newsletters related to psychedelics; the advertisement invited people to a survey about psychedelic experiences and mystical phenomena but did not mention meditation explicitly. Inclusion criteria required participants to be aged 18 or older with at least one lifetime classic psychedelic use. Of 1,315 respondents to the full survey, 875 (66.5%) reported practising some form of meditation; 345 of those indicated they had ever taken a psychedelic shortly (minutes or hours) before a formal meditation, and 256 provided free-text comments about using psychedelics before meditating. The online system prevented multiple responses from the same browser, IP addresses were not stored, and no material incentives were offered. The survey included demographic items, drug-use history, and a deliberately broad definition of "meditation"; participants selected one psychedelic they associated with meditating and then answered an open-ended prompt: "any comments you might have about using psychedelics before meditating." Type of meditation was not recorded, and respondents were not asked to describe a specific episode. Thematic analysis was performed by two authors (KA and ET) who independently examined the full set of text responses to develop an initial code set. Codes were applied, aggregated into themes and subthemes, and the structure was iteratively refined and mapped back onto the data to assess fit and prevalence. No qualitative responses were excluded prior to analysis. Quantitative summary data referenced in the paper (for example, counts of occurrences of subthemes) are available from the corresponding author upon request.

Sample characteristics: The analysed sample comprised N = 256 participants who provided text responses. Ages ranged from 18 to 72 years (mean 31.8, SD 10.8). Most respondents were male (n = 168; 65.6%), nonreligious (n = 166; 64.8%), and of White ethnicity (77.6%). Educational attainment was high (83.6% with at least a bachelor's degree). Nationalities were predominantly North American (46.5%) or British (16.8%). Psychedelic and meditation history: Participants reported a mean of 11.2 years since first psychedelic use (mean age at first use 20.6), with the most recent use on average 0.5 years prior to the survey and the most significant psychedelic experience occurring on average 4.1 years earlier. Meditation practice had been started on average 8.8 years prior; typical practice frequency was 15.9 days/month for a mean of 32.3 minutes per day. The psychedelics most commonly cited as being used prior to meditation were primarily psilocybin or LSD (specific counts in the extract refer to a table not included in the text provided). Thematic analysis identified six overarching themes, each with subthemes. Theme 1, Compatibility Between Psychedelic and Meditative States, captured participants' reports of qualitative similarity between the two states and the view that they can ‘‘work in harmony’’; many described a spontaneous drive to meditate after consuming psychedelics, including embodied or movement-based practices (Subtheme 1.1). Theme 2, Enhancement of the Meditative and Psychedelic Experience, was prevalent (103 occurrences) and described reciprocity whereby meditation amplified psychedelic effects and psychedelics deepened meditation. Reported enhancements included intensified visuals, stronger mystical or transcendent feelings, and faster onset of feelings of oneness. Subtheme 2.1 (Enhanced Meditation Experience) covered reports that psychedelics increased meditative ability, producing detached awareness or ‘‘defusion,’’ improved focus on the present, and sustained attention. Subtheme 2.1.2 (Enhanced Depth/Quality) described easier access to deep meditative states; Subtheme 2.1.3 characterised psychedelics as a "shortcut" or catalyst to meditative states that might otherwise require extended practice. Theme 3, Beneficial Changes in Relating to the Internal and External World, encompassed four subthemes. Acceptance (3.1) covered increased self-acceptance and willingness to surrender to difficult emotions; Connection (3.2) referred to a felt unity with self, others, or the universe; Peacefulness (3.3) captured enhanced calm, timelessness, and relaxation; and Transformation (3.4) described enduring shifts in perspective, compassion, and behaviour reported to extend beyond the acute episode. Theme 4, Negative Effects of Combined Use, included Becoming Overwhelmed (4.1), where some participants said the combined state could be ‘‘too intense’’ or precipitate loss of cognitive coherence, and Difficulty Meditating (4.2), where others reported impaired capacity to concentrate or maintain a meditative stance while under the drug, with some noting dose-dependent effects. Theme 5, Meditation as a Preparatory and Navigational Tool, had two subthemes. Meditation as Preparation (5.1; n = 33) described use of meditation to calm come-up anxiety, set intentions, and establish receptivity prior to psychedelic onset. Meditation to Navigate the Psychedelic Experience (5.2) captured reports that meditative skills helped manage unsettling material, eased acceptance of ego dissolution, and enabled a more controlled engagement with visuals and emotions during the trip. Theme 6, Contextual Considerations, comprised Reflections on Personal Processes (6.1) and Advice for Implementation (6.2). Participants described settings (alone, group, darkened room), ritualised approaches, and practical recommendations: attend to set and setting, have a sitter or guide, use a safe environment, and commonly favour a ‘‘right’’ or relatively low dose. Several respondents emphasised the need for proficiency or prior experience in both meditation and psychedelics to combine them safely and effectively.

Azmoodeh and colleagues interpret their findings as broadly consistent with prior experimental and theoretical work on parallels and complementarity between meditation and psychedelic states. They note that a degree of compatibility between the two states appears to be a necessary condition for mutual enhancement, and point to experimental studies (including psilocybin administration in retreat or meditative contexts) that have reported increases in meditation depth and trait mindfulness when psychedelics are combined with contemplative practice. The authors suggest clinical implications cautiously: meditation might operate as a "psychedelic-sparing" strategy in therapeutic settings, enabling therapeutically relevant subjective states (for example, mystical experiences) at lower psychedelic doses. They also propose a mechanism for enduring benefit whereby ongoing, drug-free meditation practice rehearses and consolidates adaptive changes initiated during psychedelic-meditation episodes, thus supporting longer-term transformation. At the same time, the discussion highlights safety concerns the authors acknowledged in the data. Some participants reported being overwhelmed or finding meditation and psychedelics mutually impairing; the investigators suggest this may occur when meditators lack well-developed ‘‘protective awareness’’ or when individuals are vulnerable to adverse responses to consciousness-altering practices. They stress that both meditation and psychedelics can independently provoke distressing experiences and that combined use may amplify psychological risk for some individuals. The authors emphasise limitations that temper interpretation: convenience recruitment via the internet and self-selection likely biased the sample toward people with prior positive experiences; the cross-sectional design does not permit causal inference; and the survey did not collect detailed quantitative data on timing, dosing, type of meditation, frequency of combined use, or whether different drugs interact differently with meditation. They also acknowledge that the open-ended prompt (which asked about meditating after psychedelic use) may have biased responses toward that temporal pattern. Strengths cited include a relatively large qualitative sample and independent coding by two researchers, but the authors conclude that their findings are exploratory and hypothesis-generating, pointing to conditions that may facilitate or hinder combined psychedelic and meditative practice and suggesting directions for future controlled research.